Biovie is trading 7.69% up at $2.10, with no clear catalyst identified for the move.
- The stock is extending a highly volatile rebound after rising 38.81% on August 20 and 4.84% on August 21.
- No company-specific announcement dated August 24 has been identified.
- The latest major catalyst remains the August 6 Parkinson’s trial update, but its direct connection to the August 24 move is unconfirmed; broader indices were mixed to lower, so market sentiment does not clearly explain the gain.